查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963987

基因靜默市場－全球產業規模、佔有率、趨勢、機會、預測：按產品/服務、應用、地區和競爭格局分類，2021-2031年

Gene Silencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因靜默市場預計將從 2025 年的 29.1 億美元成長到 2031 年的 44.8 億美元，複合年成長率為 7.46%。

此治療領域專注於精準抑制特定的致病基因，主要透過反義寡核苷酸和RNA干擾等機制來實現。市場成長的根本驅動力在於腫瘤和慢性遺傳疾病的日益普遍，這些疾病需要標靶分子干涉，以及脂質奈米顆粒遞送技術的顯著進步。根據美國基因與細胞治療學會（ASGCT）預測，到2025年，該產業將呈現強勁的發展勢頭，僅第二季就啟動了38項針對RNA療法的新臨床試驗，就足以證明這一點。

市場概覽
預測期 2027-2031
市場規模：2025年 29.1億美元
市場規模：2031年 44.8億美元
複合年成長率：2026-2031年 7.46%
成長最快的細分市場 RNAi
最大的市場 北美洲

儘管取得了這些進展，但基因定序劑的穩定性和細胞內遞送仍面臨許多挑戰。 RNA分子在血液中的生理性分解，以及如何在不引起脫靶毒性的情況下將大分子轉運穿過細胞膜，仍然是主要的障礙。這些技術難題持續阻礙基因沉默治療方法的廣泛商業化和臨床應用，也是限制基因靜默療法普及的主要障礙。

市場促進因素

監管核准的加速和臨床研發管線的持續拓展是全球基因靜默市場的主要驅動力，推動該領域從實驗研究走向具體的商業性化應用。隨著監管機構確認反義寡核苷酸和RNA干擾療法的安全性，針對未被滿足的醫療需求（尤其是在罕見遺傳疾病領域）的新型治療方法正加速進入市場。根據BioPharma PEG報道，2024年12月，FDA核准了TringolzaFirst-in-Class用於治療遺傳性乳糜微粒血症的RNA標靶治療。該領域的經濟可行性也得益於其商業性擴充性。例如，根據Alnilam Pharmaceuticals公司公佈的2025年第三季淨產品銷售額達到8.51億美元，年增103%。這凸顯了市場對有效基因靜默療法的強勁需求。

同時，隨著領先的製藥公司努力克服持續存在的細胞內遞送難題，策略聯盟和合作正在重塑市場動態。產業領導者正收購專業的生物技術公司，以即時獲得能夠針對肝臟以外肌肉組織的獨特遞送平台，例如抗體-寡核苷酸偶聯物。諾華公司於2025年10月宣布以約120億美元收購Avidity Biosciences，以獲得先進的RNA架構，這就是高價值整合趨勢的一個例證。這些資本密集型合作提供了必要的資金，以推動複雜的臨床試驗，加速下一代治療方法的開發，並確保永續的長期市場擴張。

市場挑戰

基因靜默劑的穩定性和細胞內遞送持續存在的挑戰是限制全球基因靜默市場擴張的一大瓶頸。儘管RNA療法具有巨大的治療潛力，但將大分子無毒無害地穿過細胞膜的技術難題常常導致臨床試驗失敗。這些遞送障礙增加了研發項目的風險，造成後期臨床試驗的高脫落率，並使監管核准之路更加複雜。因此，商業化進程被顯著延長，從而延緩了潛在根治性治療方法進入醫療體系的時間。

這種高風險環境將直接影響市場成長所需的金融生態系統，因為投資者對面臨這些尚未解決的技術挑戰的早期新創公司將更加謹慎。基礎研究經費的減少將阻礙候選藥物轉化為商業性化治療方法的進程。根據美國基因與細胞治療學會（ASGCT）預測，2025年第二季Start-Ups的資金籌措僅1.97億美元，反映出該領域投資的持續下降。資金的大幅減少將削弱產業的創新能力，進而阻礙整體市場成長。

市場趨勢

RNA生物農藥和作物保護技術的興起，代表著農業領域的變革性市場擴張，它將基因靜默原理應用於永續的害蟲管理。與頻譜化學藥劑不同，這些可生物分解的解決方案利用雙鏈RNA選擇性地沉默特定農業害蟲的關鍵基因，從而在保護益蟲的同時，最大限度地減少對環境的毒性。 2025年10月，Greenlight Biosciences公司獲得了美國環保署（EPA）頒發的「Noroa」註冊證書，標誌著這項商業性突破的實現。 Noroa是一種新型的RNA解決方案，專門用於控制和標靶化蜜蜂蜂群中的瓦蟎。

同時，表觀遺傳和轉錄基因靜默技術的出現正在建立一種新的治療範式，該範式能夠在不改變DNA序列的情況下實現持續的基因抑制。這種方法利用表觀遺傳編輯技術來調控甲基化模式等化學標記，從而在轉錄層面上有效地使疾病相關基因惰性，同時避免了雙股DNA斷裂帶來的安全風險。投資界也認知到了這種方法的潛力；例如，Epigenic Therapeutics公司於2025年9月完成了6,000萬美元的B輪資金籌措，以加速其專有基因調控平台的臨床開發。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因靜默市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品/服務分類（RNAi、CRISPR-Cas9、反義寡核苷酸、其他）
    • 依應用領域（神經學、腫瘤學、感染疾病、代謝性疾病、藥物製造等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美基因靜默市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲基因靜默市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區基因靜默市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲基因靜默市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲基因靜默市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球基因靜默市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Revvity, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28069

The Global Gene Silencing Market is projected to expand from USD 2.91 Billion in 2025 to USD 4.48 Billion by 2031, reflecting a compound annual growth rate of 7.46%. This therapeutic field focuses on the precise downregulation of specific disease-causing genes, predominantly employing mechanisms such as antisense oligonucleotides and RNA interference. The market's growth is fundamentally fueled by the increasing prevalence of oncological conditions and chronic genetic disorders that require targeted molecular interventions, alongside significant progress in lipid nanoparticle delivery technologies. According to the 'American Society of Gene & Cell Therapy', the industry saw strong developmental momentum in '2025', evidenced by the initiation of 38 new clinical trials dedicated to RNA therapies during the second quarter alone.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.91 Billion
Market Size 2031USD 4.48 Billion
CAGR 2026-20317.46%
Fastest Growing SegmentRNAi
Largest MarketNorth America

Despite these advancements, the sector encounters substantial hurdles regarding the stability and intracellular delivery of silencing agents. The physiological degradation of RNA molecules within the bloodstream, combined with the challenge of transporting large macromolecules across cellular membranes without causing off-target toxicity, remains a critical obstacle. These technical difficulties continue to impede the broad commercialization and clinical efficacy of these therapies, representing major barriers that limit the widespread adoption of gene silencing treatments.

Market Driver

Accelerated regulatory approvals and expanding clinical pipelines act as the primary catalyst for the Global Gene Silencing Market, shifting the sector from experimental research to tangible commercial realization. As regulatory agencies confirm the safety profiles of antisense and RNA interference modalities, the market entry of novel therapies has quickened, specifically addressing unmet needs in rare genetic diseases. This momentum was evident when, according to Biopharma PEG, the FDA approved Tryngolza in December 2024, a first-in-class RNA-targeted medicine for familial chylomicronemia syndrome. The financial viability of the sector is further validated by commercial scalability; for instance, according to Alnylam Pharmaceuticals, the company reported third-quarter net product revenues of $851 million in October 2025, marking a 103% year-over-year increase that underscores the strong demand for effective gene silencing interventions.

Concurrently, strategic partnerships and collaborations are reshaping market dynamics as major pharmaceutical companies strive to overcome persistent intracellular delivery challenges. By acquiring specialized biotechnology firms, industry leaders gain immediate access to proprietary delivery platforms-such as antibody oligonucleotide conjugates-that can target tissues like muscle beyond the liver. This trend of high-value consolidation is exemplified by Novartis, which, according to reports in October 2025, agreed to acquire Avidity Biosciences for approximately $12 billion to secure its advanced RNA architecture. These capital-intensive collaborations provide the necessary funding to navigate complex clinical trials and accelerate the development of next-generation modalities, ensuring sustainable long-term market expansion.

Market Challenge

The persistent difficulty regarding the stability and intracellular delivery of silencing agents acts as a critical bottleneck restricting the expansion of the Global Gene Silencing Market. Although RNA therapies offer significant therapeutic promise, the technical inability to transport large macromolecules across cellular membranes without toxicity or degradation frequently results in clinical failures. These delivery barriers increase the risk profile of developmental programs, leading to significant attrition in late-stage trials and complicating the path to regulatory approval. Consequently, the timeline for commercialization is significantly prolonged, delaying the entry of potentially curative treatments into the healthcare system.

This high-risk environment directly impacts the financial ecosystem required for market growth, as investors exercise greater caution toward early-stage ventures grappling with these unresolved technical hurdles. A contraction in available capital for foundational research stalls the progression of pipeline candidates into commercially viable treatments. According to the 'American Society of Gene & Cell Therapy', in '2025', start-up financings raised only $197 million in the second quarter, reflecting a continued decline in investment volume for the sector. This reduction in essential funding impedes the industry's ability to innovate, thereby hampering the overall trajectory of the market.

Market Trends

The rise of RNA-based biopesticides and crop protection in agriculture signifies a transformative expansion of the market, applying gene silencing principles to sustainable pest management. Unlike broad-spectrum chemical agents, these biodegradable solutions employ double-stranded RNA to selectively silence essential genes in specific agricultural pests, thereby minimizing environmental toxicity and preserving beneficial insects. This commercial breakthrough was highlighted when, according to GreenLight Biosciences, the company received registration from the U.S. Environmental Protection Agency in October 2025 for Norroa, a novel RNA-based solution specifically designed to control and target Varroa mites in honeybee colonies.

Simultaneously, the emergence of epigenetic and transcriptional gene silencing is establishing a new therapeutic paradigm that achieves durable gene repression without altering the underlying DNA sequence. This approach leverages epigenetic editors to modulate chemical markers, such as methylation patterns, effectively turning off disease-associated genes at the transcriptional level while avoiding the safety risks associated with double-strand DNA breaks. The investment community has recognized the potential of this modality; for instance, according to Epigenic Therapeutics, in September 2025, the company completed a $60 million Series B financing round to accelerate the clinical development of its proprietary gene modulation platform.

Key Market Players

  • Revvity, Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • GenScript Biotech Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • New England Biolabs, Inc.

Report Scope

In this report, the Global Gene Silencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Silencing Market, By Product & Service

  • RNAi
  • CRISPR-Cas9
  • Antisense Oligonucleotides
  • Others

Gene Silencing Market, By Application

  • Neurology
  • Oncology
  • Infectious Diseases
  • Metabolic Diseases
  • Therapeutics Manufacturing
  • Others

Gene Silencing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Silencing Market.

Available Customizations:

Global Gene Silencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Silencing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (RNAi, CRISPR-Cas9, Antisense Oligonucleotides, Others)
    • 5.2.2. By Application (Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Gene Silencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gene Silencing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Gene Silencing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Gene Silencing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Application

7. Europe Gene Silencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gene Silencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Application
    • 7.3.2. France Gene Silencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Gene Silencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Gene Silencing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Gene Silencing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Application

8. Asia Pacific Gene Silencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Gene Silencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Application
    • 8.3.2. India Gene Silencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Gene Silencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Gene Silencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Gene Silencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Application

9. Middle East & Africa Gene Silencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Gene Silencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Gene Silencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Gene Silencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Application

10. South America Gene Silencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Gene Silencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Gene Silencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Gene Silencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Gene Silencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Revvity, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Danaher Corporation
  • 15.3. Agilent Technologies, Inc.
  • 15.4. GenScript Biotech Corporation
  • 15.5. Merck KGaA
  • 15.6. Thermo Fisher Scientific, Inc.
  • 15.7. Illumina, Inc.
  • 15.8. Bio-Rad Laboratories, Inc.
  • 15.9. Bio-Techne Corporation
  • 15.10. New England Biolabs, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer